Please login to the form below
Parexel appoints CEO
Jamie Macdonald succeeds co-founder Josef von Rickenbach
Biopharmaceutical services provider, Parexel, has appointed Jamie Macdonald as its chief executive officer (CEO), a role that will see him succeed Josef von Rickenbach.
Macdonald previously led INC Research, now known as Syneos Health, for several years first as CEO and most recently as vice chairman.
He has also served as senior vice president and head of global project management at Quintiles, now IQVIA.
Macdonald said: “As a trail blazer in the biopharmaceutical services industry, the company enjoys well-deserved recognition as having the kind of deep therapeutic and functional expertise, global reach and innovative capability to continue its leadership.
“I am humbled to have the opportunity to build on this legacy and look forward to continued growth and excellence for Parexel.”
Subscribe to our email news alerts
- Account Director, Healthcare Marketing Creative Agency, Fixed te...
- Highly competitive salary
- Account Manager, 6 month contract, Healthcare Brand communicatio...
- Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
- Highly competitive salary
- Home Based Account Manager, Medical Communications, UK, Pharma/M...
- Highly competitive salary
- Account Manager, Healthcare Marketing Creative Agency, Fixed ter...
- Highly competitive salary
- Senior Medical Copywriter - Highly Awarded Advertising Agency
- £50,000 - £60,000 yearly
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
- BMS and Janssen’s antithrombotic granted FDA fast track designation
- Sanofi's frexalimab shows promise in relapsing forms of MS
- EMA recommends revoking marketing authorisation for Novartis’ sickle cell disease drug
- Pfizer’s antibiotic combination shows promise in treating multi-drug resistant infections
- Amgen reports positive results for Otezla in psoriatic arthritis
- Medscape Education is Focusing on Patient Centricity and Education Outcomes at EHA 2023
- Pfizer reports positive results for elranatamab in multiple myeloma
- Amgen’s Lumakras shows promise in phase 3 lung cancer study
- Adaptive innovation
- Archetypes: Rethinking go-to-market expectations to drive commercial success
- Navigating patients step by step on their clinical trial journey
No results were found
PMHub
Oncosec
OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...
Latest intelligence
- Archetypes: Rethinking go-to-market expectations to drive commercial success
- In this white paper, our consultants analyze trends spanning global policy developments, rising inflation, and increasingly complex customer journeys, and reveal a new data-driven approach to archetyping that crystalizes the...
- Tuberculosis – why it remains a major global public health challenge
- Innovative collaboration is required to address the major public health challenges around TB and expedite drug development...
- Whitepaper: Closing the gap with compelling healthcare communications
- Want to learn how to close the distance between a person’s current health and their healthiest possible self?...
